-

MTTI Announces Dr. Danielle Meyrick to Lead Medical Team

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer. Dr. Meyrick brings more than 20 years of medical research, targeted radiotherapeutic (TRT) development and leadership to MTTI. She has held Chief Medical Officer roles across radiopharmaceutical organizations including Telix Pharmaceuticals and ITM Radiopharm. Dr. Meyrick will lead MTTI’s medical team to advance clinical development of lead assets, EVA101 and EVA 102 and further progress the company’s radiopharmaceutical pipeline.

“My career goal in the TRT area has always been to improve care and outcomes for cancer patients. I believe MTTI is an exciting company with technology that is able to deliver on this goal. Our unique EvaThera platform has demonstrated the ability to enhance delivery of radiation to tumors, minimize off-target activity and reduce dosing requirements —collectively offering a potentially safer, more effective approach to TRT. I am thrilled to be supporting the team in leading EVA101 and EVA102 through the critical final stages of development,” said Danielle Meyrick, CMO of MTTI.

Dr. Chris Pak, President & CEO commented “MTTI is delighted to welcome Dr. Danielle Meyrick, an experienced clinician and executive. Her perspective and track record in TRT development are key complements to our team as we expedite advancement of our targeted radiotherapeutic pipeline.”

Molecular Targeting Technologies, Inc. (MTTI). MTTI is a private, clinical stage biotech developing targeted radiotherapeutics (TRT). MTTI is committed to building value by translating innovative TRT to improve human healthcare. For more information: www.mtarget.com.

Contacts

Chris Pak, Email: cpak@mtarget.com

Industry:

Molecular Targeting Technologies, Inc.

Release Versions
English

Contacts

Chris Pak, Email: cpak@mtarget.com

More News From Molecular Targeting Technologies, Inc.

Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage biotechnology company developing next-generation radiopharmaceutical platform technologies, today announced that clinical data from 81 patients—the largest reported clinical dataset for an albumin-binding radiotherapeutic—will be presented at the 5th Targeted Radiopharmaceuticals Summit. The dataset provides what the Company believes is the first clinical validation of its proprietary Evans Blue...

MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics, today announced updated clinical findings from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with its lead investigational product candidate, ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE), following presentation at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annu...

Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announced the clinical findings of the Next-Generation PRRT, ¹⁷⁷Lu-DOTA-EB-TATE to treat GEP-NET Patients. The Phase 1 dose-escalation and dosimetry study will be presented at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place May 29–June 3, 2026, in Los Angeles, California. Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring...
Back to Newsroom